Latest End point of clinical trials Stories
SUNNYVALE, Calif., May 1, 2015 /PRNewswire/ -- Pharmacyclics, Inc.
Patients Too Sick for Enrollment in Phase III Trial for Newly Diagnosed GBM BETHESDA, Md., March 27, 2015 /PRNewswire/ -- Northwest Biotherapeutics, Inc.
Analysis of 285 Patient Subgroup Shows an Impressive Statistically Significant 59% Improvement in Overall Survival LAWRENCEVILLE, N.J., Feb.
Aldoxorubicin Demonstrates 2-Fold Increase in Likelihood of Surviving More than 2 Years versus Doxorubicin and 27% Reduction in the Risk of Death LOS ANGELES, Jan.
Continued Positive Trends in Overall Survival and Progression-Free Survival; LOS ANGELES, Nov. 14, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd.
SUNNYVALE, Calif., Oct. 17, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
AUSTIN, Texas, Sept.
New research suggests that how quickly mesothelioma progresses after treatment may predict the likelihood of survival better than treatment response. Raleigh,
Important New Variable Covered. Threshold for Meeting Primary Endpoint Lowered. BETHESDA, Md., Aug.
Latest Data Sweep from a 285 Patient Subgroup Shows An Impressive 57% Improvement in Overall Survival LAWRENCEVILLE, N.J., July 28, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: